HomeCompareCYBE vs PFE

CYBE vs PFE: Dividend Comparison 2026

CYBE yields 3.70% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $25.7K in total portfolio value· pulled ahead in Year 9
10 years
CYBE
CYBE
● Live price
3.70%
Share price
$54.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$469.91
Full CYBE calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CYBE vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYBEPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYBE + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYBE pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYBE
Annual income on $10K today (after 15% tax)
$314.81/yr
After 10yr DRIP, annual income (after tax)
$399.42/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $22,729.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYBE + PFE for your $10,000?

CYBE: 50%PFE: 50%
100% PFE50/50100% CYBE
Portfolio after 10yr
$38.3K
Annual income
$13,840.22/yr
Blended yield
36.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CYBE
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYBE buys
0
PFE buys
0
No recent congressional trades found for CYBE or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYBEPFE
Forward yield3.70%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$25.4K$51.1K
Annual income after 10y$469.91$27,210.54
Total dividends collected$4.2K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CYBE vs PFE ($10,000, DRIP)

YearCYBE PortfolioCYBE Income/yrPFE PortfolioPFE Income/yrGap
1$11,070$370.37$9,161$701.38+$1.9KCYBE
2$12,228$383.19$8,610$859.79+$3.6KCYBE
3$13,480$395.59$8,366$1,081.25+$5.1KCYBE
4$14,831$407.55$8,483$1,405.66+$6.3KCYBE
5$16,288$419.06$9,084$1,907.24+$7.2KCYBE
6$17,859$430.13$10,418$2,732.78+$7.4KCYBE
7$19,550$440.74$13,007$4,193.56+$6.5KCYBE
8$21,369$450.91$18,010$7,005.87+$3.4KCYBE
9← crossover$23,325$460.63$28,216$12,979.89$4.9KPFE
10$25,428$469.91$51,081$27,210.54$25.7KPFE

CYBE vs PFE: Complete Analysis 2026

CYBEStock

CyberOptics Corporation designs, develops, manufactures, and markets high precision sensing technology solutions and system products for inspection and metrology worldwide. It offers products based on multi-reflection suppression (MRS) technology, including multi-function systems for inspection and metrology; MX3000 memory module inspection system; 3D NanoResolution MRS sensor and WX3000 inspection and metrology system for semiconductor wafer and advanced packaging inspection and metrology; high precision 3D and 2D sensors; 3D MRS sensors; SMT electronic assembly alignment sensors; and inspection and metrology systems. The company also provides automated optical inspection (AOI) products; SQ3000 multi-function systems; QX Series 2D AOI products; MX products for inspection of memory modules; SPI Products; and semiconductor wafer and advanced packaging products. In addition, it offers general industrial metrology products and services, such as CyberGage360, a near-line or off-line metrology tool; and 3D scanning and metrology equipment, as well as semiconductor, automatic leveling, automatic gapping, automatic teaching, automatic vibration, WaferSense airborne particle, in-line particle, WaferSense auto multi, WaferSense 300mm auto resistance, and WaferSense auto vibration and leveling sensors. The company sells its products to SMT electronic assembly circuit board manufacturers, end-user customers manufacturing their own circuit boards, semiconductor manufacturers, and outsourced semiconductor assembly and test companies through independent sales representatives and distributors. CyberOptics Corporation was founded in 1984 and is headquartered in Minneapolis, Minnesota.

Full CYBE Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CYBE vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYBE vs SCHDCYBE vs JEPICYBE vs OCYBE vs KOCYBE vs MAINCYBE vs JNJCYBE vs MRKCYBE vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.